全文获取类型
收费全文 | 98505篇 |
免费 | 10726篇 |
国内免费 | 2475篇 |
专业分类
耳鼻咽喉 | 441篇 |
儿科学 | 1886篇 |
妇产科学 | 1106篇 |
基础医学 | 8220篇 |
口腔科学 | 3065篇 |
临床医学 | 11697篇 |
内科学 | 11898篇 |
皮肤病学 | 1124篇 |
神经病学 | 6647篇 |
特种医学 | 2150篇 |
外国民族医学 | 13篇 |
外科学 | 7891篇 |
综合类 | 13586篇 |
一般理论 | 26篇 |
预防医学 | 9173篇 |
眼科学 | 996篇 |
药学 | 17515篇 |
533篇 | |
中国医学 | 9208篇 |
肿瘤学 | 4531篇 |
出版年
2024年 | 146篇 |
2023年 | 2167篇 |
2022年 | 2782篇 |
2021年 | 5106篇 |
2020年 | 5812篇 |
2019年 | 4533篇 |
2018年 | 4201篇 |
2017年 | 4569篇 |
2016年 | 4238篇 |
2015年 | 3698篇 |
2014年 | 6743篇 |
2013年 | 8168篇 |
2012年 | 5651篇 |
2011年 | 6139篇 |
2010年 | 4497篇 |
2009年 | 4430篇 |
2008年 | 4300篇 |
2007年 | 4317篇 |
2006年 | 3673篇 |
2005年 | 3107篇 |
2004年 | 2684篇 |
2003年 | 2376篇 |
2002年 | 1975篇 |
2001年 | 1702篇 |
2000年 | 1310篇 |
1999年 | 1133篇 |
1998年 | 985篇 |
1997年 | 901篇 |
1996年 | 827篇 |
1995年 | 813篇 |
1994年 | 734篇 |
1993年 | 643篇 |
1992年 | 668篇 |
1991年 | 595篇 |
1990年 | 540篇 |
1989年 | 547篇 |
1988年 | 488篇 |
1987年 | 460篇 |
1986年 | 409篇 |
1985年 | 548篇 |
1984年 | 486篇 |
1983年 | 326篇 |
1982年 | 407篇 |
1981年 | 318篇 |
1980年 | 317篇 |
1979年 | 232篇 |
1978年 | 235篇 |
1977年 | 177篇 |
1976年 | 212篇 |
1975年 | 99篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 探讨不同时期慢性阻塞性肺疾病(COPD)患者血清诱饵受体3(DcR3)、凋亡抑制蛋白(Survivin)表达水平及临床意义。方法 选取2018年9月—2019年12月本院收治的92名COPD患者为研究对象,其中稳定型COPD 50例,急性加重期COPD 42例;同期本院健康体检者88例为对照组。测定各组研究对象血清DcR3、Survivin水平及肺功能指标。 与对照组[DcR3(106.54±48.35)pg/mL,Survivin(98.85±26.59)pg/mL]比较,稳定期组和急性加重期组血清DcR3[(395.23±123.85)pg/mL,(1 248.81±213.59)pg/mL]、Survivin [(267.54±84.69)pg/mL,(1 233.95±307.26)pg/mL]水平升高;与稳定期组比较,急性加重期组血清DcR3、Survivin水平升高。与对照组比较,稳定期组和急性加重期组FEV1%、FEV1 /FVC、DLCO%水平降低(P<0.001);与稳定期组比较,急性加重期组FEV1%、FEV1 /FVC、DLCO%水平降低(P<0.001)。随着低氧血症严重程度的增加,COPD患者血清DcR3、Survivin水平逐渐增加(P<0.001)。多因素logistics回归分析显示,高水平DcR3、Survivin、IL-12、hs-CRP为COPD病情的危险因素(P<0.001)。DcR3、Survivin与FEV、FEV1 /FVC呈负相关,与IL-12、TNF-α、hs-CRP呈正相关(P<0.001)。 COPD稳定期、急性加重期患者血清DcR3、Survivin表达水平升高,且DcR3、Survivin与COPD病情严重程度呈正相关。 相似文献
2.
目的 基于《国际功能、残疾和健康分类》(ICF)构建智力和发展性残疾儿童青少年身体活动效益系统综述的范畴和PICO架构,探讨智力和发展性残疾儿童和青少年参加身体活动的健康效益。 相似文献
3.
4.
《European journal of surgical oncology》2022,48(5):1062-1067
BackgroundSurgical resection is recommended for patients with resectable acinar cell carcinoma (ACC). The aim of this study was to investigate the clinical characteristics and surgical outcomes of resectable ACC in comparison to pancreatic ductal adenocarcinoma (PDAC).MethodA retrospective analysis was performed on all patients who consecutively underwent radical resection with pathologically confirmed ACC and PDAC from December 2011 to December 2018. Clinicopathologic characteristics and follow-up information were analyzed. A 1:3 propensity score matching (PSM) method was used to minimize the bias between ACC and PDAC.ResultsA total of 26 patients with ACC and 1351 with PDAC were included. Compared to PDAC, ACC tended to be larger (4.5 vs. 3.0 cm; p < 0.001) and more frequently located in the pancreatic body/tail (61.5% vs. 36.6%, p = 0.009), with lower total bilirubin levels, lower neutrophil lymphocyte ratio (NLR) levels and lower carbohydrate antigen 19-9 (CA19-9) levels and carcinoembryonic antigen (CEA) levels. There was no difference in postoperative morbidities in patients with ACC and PDAC. The median OS and RFS were longer in ACC when compared to PDAC (OS: 43.5 mo vs. 19.0 mo, p = 0.004; RFS: 24.5 mo vs. 11.6 mo, p = 0.023). After the 1:3 PSM, ACC remained to be a better histological type for OS (p = 0.024), but had comparable RFS with PDAC (p = 0.164).ConclusionPatients with ACC after radical resection had better OS than that with PDAC. However, ACC is also an aggressive tumor with a similar trend of RFS with PDAC after the matching, necessitating the multidisciplinary treatment for resectable ACC disease. 相似文献
5.
6.
Christopher Meyers 《The Hastings Center report》2023,53(1):26-27
In Abram Brummett and Erica K. Salter's excellent paper, “Mapping the Moral Terrain of Clinical Deception,” they rightly note that it is sometimes ethically appropriate for health care professionals to deceive patients and families. However, they also note that because doing so violates a prima facie duty of honesty, the ethical burden of proof falls upon the deceiver. Hence, they also provide a sophisticated framework for determining whether any given case is warranted. I applaud their overall approach but also critique some of their claims, in particular, their conclusion that lies of commission require greater justification than those of omission and their conflation of the principles of beneficence and nonmaleficence. I also urge them to give greater attention to how power asymmetries should be accounted for and to the impact such deceptive choices might have on the clinician's character. 相似文献
7.
8.
Kyung-Suk Suh Suk Kyun Hong Sola Lee Su young Hong Sanggyun Suh Eui Soo Han Seong-Mi Yang YoungRok Choi Nam-Joon Yi Kwang-Woong Lee 《American journal of transplantation》2022,22(1):260-265
Minimally invasive approaches are increasingly being applied in surgeries and have recently been used in living donor hepatectomy. We have developed a safe and reproducible method for minimally invasive living donor liver transplantation, which consists of pure laparoscopic explant hepatectomy and pure laparoscopic implantation of the graft, which was inserted through a suprapubic incision. Pure laparoscopic explant hepatectomy without liver fragmentation was performed in a 60-year-old man with alcoholic liver cirrhosis and hepatocellular carcinoma. The explanted liver was retrieved through a suprapubic incision. A modified right liver graft, procured from his 24-year-old son using the pure laparoscopic method, was inserted through a suprapubic incision, and implantation was performed intracorporeally throughout the procedure. The time required to remove the liver was 369 min, and the total operative time was 960 min. No complications occurred during or after the surgery. The patient recovered well, and his hospital stay was of 11 days. Pure laparoscopic living donor liver transplantation from explant hepatectomy to implantation was performed successfully. It is a feasible procedure when performed by a highly experienced surgeon and transplantation team. Further studies with larger sample sizes are needed to confirm its safety and feasibility.
9.
10.
Matthias Knefel PhD Elisabeth L. Zeilinger PhD Simone Lubowitzki PhD Katharina Krammer MSc Matthias Unseld MD Rupert Bartsch MD Thorsten Fuereder MD Ulrich Jäger MD Barbara Kiesewetter MD Maria Krauth MD Markus Raderer MD Philipp B. Staber MD Peter Valent MD Alexander Gaiger MD 《Cancer》2023,129(21):3466-3475